Triasima Portfolio Management’s Royalty Pharma RPRX Stock Holding History

Triasima Portfolio Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.1M	Buy	+180,710	New	+$9.41M	1.37%	21

Other funds holding RPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

KMC

Kirr Marbach & Co Columbus, Indiana $594M AUM 34% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Cooper Investors Melbourne, Victoria, Australia $218M AUM 0.39% 1-Year Est. Return

Triasima Portfolio Management's RPRX Position: Q2 2026 in Review

Triasima Portfolio Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 180,710 shares worth $10.1M. The stake represents 1.37% of the portfolio and ranks #21 among its holdings.

73 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Triasima Portfolio Management held 180,710 shares of Royalty Pharma worth $10.1M as of Q2 2026.
Royalty Pharma was a new Triasima Portfolio Management position in Q2 2026.
Royalty Pharma made up 1.37% of Triasima Portfolio Management's portfolio in Q2 2026, its #21 holding.
73 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Triasima Portfolio Management's 13F filing for Q2 2026, filed 21 Jul 2026.